PET/CT: Benefits for Brain Tumour Radiotherapy

10 Nov 2018
16:35 - 16:55

PET/CT: Benefits for Brain Tumour Radiotherapy

  • Background

This section will cover the basic principles of PET-CT imaging, explaining that this hybrid imaging modality benefits by displaying both from anatomical and functional information of the pathology under investigation. In addition, there will be a brief introduction on oncology terminology used in radiotherapy (GTV, CTV and PTV) and how the data from PET-CT can be used to affect these volumes.

  • Diagnostic Tests available

List of commonly used radiopharmaceuticals with a focus on the radiopharmaceuticals used in brain oncology: 11C-methionine (MET), 18F-fluoro-L-thymidine (FTL) and 18F-fluoro-ethyl-tyrosine (FET)

  • PET-CT: Target localisation in therapy (focus on Brain)

Results from studies that show how these radiopharmaceuticals are used to alter the GTV, CTV and PTV and the Intra- and inter-observer variability between tumour delineation from MR, CT and PET/CT images as well as fusion of images from the aforementioned modalities.

  • Conclusion

Conclusions and recommendations of the speaker for the assessment of all the variables that would result in a minimum effect on the most accurate tumour volume delineation resulting in the sparing of healthy tissue and the best tumour control probability.